|
KMID : 1038920180170040083
|
|
Annals of Optometry and Contact Lens
2018 Volume.17 No. 4 p.83 ~ p.88
|
|
|
Update on Diagnosis and Treatment of Retinopathy of Prematurity
|
|
Heo Hwan
|
|
|
Abstract
|
|
|
|
Retinopathy of prematurity is still the leading cause of blindness in children. It is on the rise due to the development of postnatal care technology in developing and developed countries. However, due to the lack of experts, appropriate diagnosis and treatment are often not available. Therefore, it is necessary to develop technologies such as telemedicine and diagnostic automation technology for retinopathy of prematurity. Experts should know that the difference of timing and nature of recurrence between intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection and laser treatment. And, after verifying safety dose and systemic complication, guidelines for safe use of intravitreal anti-VEGF injection should be developed.
|
|
|
KEYWORD
|
|
|
Bevacizumab, Ranibizumab, Retinopathy of prematurity, Telemedicine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|